Announcing our newest cancer test. Screen cancer early with Onco-D-clare. Learn more
In 2004, genetics pioneer Dr. Ioannis Papasotiriou founded RGCC with a steadfast commitment to personalized cancer care. Driven by his unwavering belief in the power of a patient's genes, Dr. Papasotiriou has passionately refused to access external funding that could compromise his vision and commitment to a science-driven cancer solution.
His dedication and expertise have enabled RGCC to stand at the forefront of cancer treatment, providing hope and healing to patients and their families around the world.
“If you bring in investors, they want profitability - as quickly as possible - they don’t care about the outcome.
For us, our interest is what we could do better than the protocols available in the clinical practice, so we can create better treatments, no matter whether we use current drugs or develop new treatments.
We reinvest 85% of our income directly into further research which we wouldn’t be able to do if we brought in external investors.”
- Dr. Ioannis Papasotiriou
Dr. Ioannis Papasotiriou was born in Munich, Germany, and graduated from the Medical School of Thessaloniki University, Greece, in 1997. He specialized in both Human Genetics (University of Zurich) and Hematology Oncology (MLU/UKH/Halle/Saale).
He completed a Master's degree in Molecular Biology in Medicine from Westminster University and a second Master’s degree in Oncology from the University of Nottingham.
He completed his doctoral degree (MD, Ph.D.) at MLU University in the area of TKIs in human cancer cell lines. Between 2001 and 2004, he established Arzt Genetik Zentrum in Thessaloniki, where he was the director.
In May 2004, Dr. Papasotiriou established R.G.C.C. INTERNATIONAL GmbH to specialize in molecular oncology, focusing on cancer stem cells or circulating tumor cells (CTC).
Since 2015, Dr. Papasotiriou is also a certified cytometry (Class A) qualified person for German authorities (Bundes Pharmazeutika), and Responsible Person (RP) for Swissmedic.
Dr. Papasotiriou has been a certified ICH-GCP (EU, FDA) consultant since 2018.